Andy Mulvaney, Non-executive Director

Andy is a seasoned industry executive with almost 20 years of hands-on experience at all stages of development of biotech companies.  Andy was co-founder of VASTox and, as part of the senior team, led the company through to IPO (LSE:AIM), subsequently Summit Therapeutics (NASDAQ:SMMT).  Andy then led the business development efforts for the company for over 10 years.  More recently Andy was COO at OxStem Ltd.

Andy holds a PhD in organometallic chemistry from Cardiff University and was a postdoctoral fellow in the field of combinatorial chemistry and asymmetric synthesis at the University of Oxford Dyson Perrins Laboratory for over 7 years where he led external collaborations.